Nijmegen, the Netherlands, June 11, 2019 – The Dutch company Xenikos B.V., which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, announced today that the U.S. Food and Drug Administration (FDA)...
• Phase I clinical trial to evaluate safety and tolerability of ATR-002 in healthy volunteers • ATR-002 expected to show high resilience to viral resistance and prolonged treatment window • Novel approach to treating influenza, one of the most prominent global health...
Today LightOx Ltd, a North East based company announces the appointment of two new Non-Executive Directors to its board. Newcastle upon Tyne, UK, 2nd May 2019 Mr Paul Lelieveld and Dr Frans van Dalen have joined the LightOx team and will support the development of new...
Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of...
Galapagos GLPG€87,94+0,83% heeft vorig jaar zijn omzet verdubbeld en het verlies weten terug te brengen. Het biotechbedrijf kwam donderdag na het sluiten van de Amerikaanse beurs met cijfers en spreekt zelf van een ‘uitzonderlijk sterke” balans. De omzet...
